Fingolimod: systemic complications
Evidence-based neurology checklist on fingolimod: systemic complications: Lymphopaenia Caused by redistribution of lymphocytes in secondary lymphoid organs Especially in women with a low body mass index (BMI) It is worse if the baseline lymphocyte count was low It may persist after discontinuation…
Lymphopaenia
- Caused by redistribution of lymphocytes in secondary lymphoid organs
- Especially in women with a low body mass index (BMI)
- It is worse if the baseline lymphocyte count was low
- It may persist after discontinuation of treatment
Malignant adverse effects
Cardiac adverse effects
Fingolimod associated macular edema (FAME)
Other ophthalmological adverse effects
Opportunistic infections
Other systemic complications
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25:673-689.
- Kappos L, Radue EW, O'Connor P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. NEJM 2010; 362:387-401.
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing−remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:545–556.
- Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575.
- And 45 more. Subscribe to see the full list
